Colotta F, Orlando S, Fadlon E J, Sozzani S, Matteucci C, Mantovani A
Istituto di Ricerche Farmacologiche Mario Negri, Centro Daniela e Catullo Borgomainerio, Milano, Italy.
J Exp Med. 1995 Jun 1;181(6):2181-6. doi: 10.1084/jem.181.6.2181.
Molecules representative of different classes of chemotactic agents, including formyl-Met-Leu-Phe (FMLP), C5a, leukotriene B4, platelet-activating factor, and interleukin (IL)-8, caused a rapid reduction in the IL-1 binding capacity by human polymorphonuclear leukocytes (PMN), a cell type expressing predominantly the IL-1 type II decoy receptor (IL-1 decoy RII). N-t-Boc-Met-Leu-Phe, an antagonist for the FMLP receptor, inhibited the loss of IL-1 binding capacity induced by FMLP. Monocyte chemotactic protein 1, a chemokine related to IL-8 but inactive on PMN, had no effect on IL-1 binding in this cell type. FMLP was selected for further detailed analysis of chemoattractant-induced loss of IL-1 binding by PMN. The action of FMLP was rapid, reaching 50% of its maximum (80%) at 30 s, the earliest measurable time point, and plateauing between 10 and 30 min. Dose-response analysis revealed that maximal reduction of IL-1 binding was reached at FMLP concentrations that were also optimal for chemotaxis (50% effective dose = 5 x 10(-9) M). The loss of IL-1 binding capacity caused by FMLP was determined by a reduction in receptor number with no change in their affinity. The effect of FMLP on IL-1 receptor (IL-1R) was selective in that the PMN surface structures IL-8R, CD16, CD18, and major histocompatibility complex class I antigens were unaffected under these conditions. Loss of surface IL-1R was not due to an augumented rate of internalization. FMLP caused rapid release of a 45-kD IL-1-binding molecule identified as the IL-1 decoy RII. After FMLP-induced release, PMN reexpressed newly synthesized receptors, reaching basal levels by 4 h. FMLP-induced release of the IL-1 decoy RII did not impair the responsiveness of PMN to IL-1 in terms of promotion of survival and cytokine production. FMLP-induced release of the IL-1 decoy RII was unaffected by protein synthesis inhibitors, was blocked by certain protease inhibitors, and was mimicked by agents (the Ca++ ionophore A23187 and phorbol myristate acetate) that recapitulate elements in the signal transduction pathway of chemoattractant receptors. The time frame and concentration range of chemoattractant-induced rapid release of the IL-1 decoy RII are consistent with the view that IL-1 decoy RII release is an early event in the multistep process of leukocyte recruitment.(ABSTRACT TRUNCATED AT 400 WORDS)
不同类别的趋化因子的代表性分子,包括甲酰甲硫氨酰亮氨酰苯丙氨酸(FMLP)、C5a、白三烯B4、血小板活化因子和白细胞介素(IL)-8,可使人多形核白细胞(PMN)的IL-1结合能力迅速降低,PMN是一种主要表达IL-1 II型诱饵受体(IL-1诱饵RII)的细胞类型。N-叔丁氧羰基甲硫氨酰亮氨酰苯丙氨酸是FMLP受体的拮抗剂,可抑制FMLP诱导的IL-1结合能力丧失。单核细胞趋化蛋白1是一种与IL-8相关但对PMN无活性的趋化因子,对这种细胞类型中的IL-1结合没有影响。选择FMLP对PMN趋化因子诱导的IL-1结合丧失进行进一步详细分析。FMLP的作用迅速,在最早可测量的时间点30秒时达到其最大值(80%)的50%,并在10至30分钟之间达到平稳状态。剂量反应分析表明,在对趋化性也最适宜的FMLP浓度下(50%有效剂量 = 5×10⁻⁹ M),IL-1结合的最大降低得以实现。FMLP导致的IL-1结合能力丧失是由受体数量减少而其亲和力不变所决定的。FMLP对IL-1受体(IL-1R)的作用具有选择性,因为在这些条件下,PMN表面结构IL-8R、CD16、CD18和主要组织相容性复合体I类抗原未受影响。表面IL-1R的丧失并非由于内化速率增加。FMLP导致一种被鉴定为IL-1诱饵RII的45-kD IL-1结合分子迅速释放。FMLP诱导释放后,PMN重新表达新合成的受体,4小时后达到基础水平。FMLP诱导的IL-1诱饵RII释放并不损害PMN在促进存活和细胞因子产生方面对IL-1的反应性。FMLP诱导的IL-1诱饵RII释放不受蛋白质合成抑制剂的影响,被某些蛋白酶抑制剂阻断,并被模拟趋化因子受体信号转导途径中元件的试剂(钙离子载体A23187和佛波酯肉豆蔻酸酯乙酸)所模拟。趋化因子诱导的IL-1诱饵RII快速释放的时间框架和浓度范围与IL-1诱饵RII释放是白细胞募集多步骤过程中的早期事件这一观点一致。(摘要截断于400字)